9/28/2026
Psyence BioMed secures exclusive U.S. ibogaine license
Texas Ibogaine Research Corporation to lead U.S. ibogaine drug development.
Topic archive
psyence biomed ltd.
4 stories
9/23/2026
Psyence BioMed invests $5M in PsyLabs for U.S. ibogaine program
Investment aims to bolster ibogaine research for opioid use disorder in Texas.
8/19/2026
Psyence BioMed backs Trump ibogaine initiative
Company aligns with U.S. efforts to advance ibogaine research.
8/8/2026
Psyence BioMed focuses on psilocybin and ibogaine supply
The biotech firm aims for vertical integration in psychedelic therapeutics.